WOCKHARDT PHARMA : Wockhardt Limited approves raising funds upto Rs. 150 crore
#Wockhardt #FundRaising
#Wockhardt #FundRaising
#1QWithCNBCTV18 | #Wockhardt reports #Q1 earnings
- Net loss at ₹134 cr vs loss of ₹67 cr (YoY)
- Other income at ₹14 cr vs ₹57 cr (YoY)
- One-time loss at ₹14 cr vs nil
- Revenue up 8.0% at ₹644 cr vs ₹595 cr (YoY)
- EBITDA at ₹16 cr vs EBITDA loss of ₹16 cr (YoY)… https://t.co/EvntpPwomp https://t.co/tnW4bt23c8
- Net loss at ₹134 cr vs loss of ₹67 cr (YoY)
- Other income at ₹14 cr vs ₹57 cr (YoY)
- One-time loss at ₹14 cr vs nil
- Revenue up 8.0% at ₹644 cr vs ₹595 cr (YoY)
- EBITDA at ₹16 cr vs EBITDA loss of ₹16 cr (YoY)… https://t.co/EvntpPwomp https://t.co/tnW4bt23c8
#JustIn | #Wockhardt: MiqnafTM (Nafithromycin) receives favourable recommendation from Central Drugs Standard Control Organization (CDSCO) for treatment of Community-Acquired Bacterial Pneumonia (CABP)